10-Q: Enhabit Inc. Reports Q3 2024 Results, Impacted by Goodwill Impairment

Enhabit Inc. reported a net loss for Q3 2024, primarily due to a significant goodwill impairment charge, despite some improvements in cost management.

Summary

• Enhabit Inc. reported a net loss of $110.2 million for the third quarter of 2024, compared to a net loss of $2.4 million in the same period last year.
• The company's net service revenue decreased by 1.8% to $253.6 million in Q3 2024, down from $258.3 million in Q3 2023.
• A significant goodwill impairment charge of $107.9 million was recorded in Q3 2024, impacting the home health reporting unit.
• For the nine months ended September 30, 2024, the net loss was $110.2 million, compared to a net loss of $74.1 million for the same period in 2023.
• The company's cost of service, excluding depreciation and amortization, decreased slightly to $131.7 million in Q3 2024.
• General and administrative expenses also decreased to $103.8 million in Q3 2024, due to cost control initiatives.
• The company's adjusted EBITDA was $24.5 million for Q3 2024, compared to $23.2 million in Q3 2023.
• The company's home health segment saw a decrease in revenue, while the hospice segment experienced growth.
• The company terminated a contract with UnitedHealth Group, which will be effective January 31, 2025, and is working to replace that revenue with other payors.
• The company estimates a loss of approximately $2 million in net service revenue and adjusted EBITDA due to the impact of Hurricanes Helene and Milton.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to the significant net loss and goodwill impairment, despite some positive aspects like cost control and hospice growth. The termination of a major contract also adds uncertainty.

Positives

• Cost of service, excluding depreciation and amortization, decreased slightly in Q3 2024.
• General and administrative expenses decreased due to cost control initiatives.
• The hospice segment experienced revenue growth due to increased patient days and Medicare reimbursement rates.
• The company's adjusted EBITDA increased year-over-year in Q3 2024.
• The company is actively shifting business to Medicare Advantage contracts with improved rates.

Negatives

• The company reported a significant net loss of $110.2 million in Q3 2024.
• Net service revenue decreased by 1.8% year-over-year in Q3 2024.
• The home health segment experienced a decrease in revenue due to lower Medicare recertifications.
• The company recorded a $107.9 million goodwill impairment charge in Q3 2024.
• The termination of the UnitedHealth Group contract may impact future revenue if not replaced effectively.
• The company estimates a $2 million loss in net service revenue and adjusted EBITDA due to Hurricanes Helene and Milton.

Risks

• The company faces risks related to regulatory changes impacting reimbursement rates.
• The company's ability to attract and retain key personnel is a risk.
• Potential disruptions or breaches of information systems could negatively impact operations.
• The outcome of litigation could have a material adverse effect on the company.
• The company's ability to control costs, particularly labor and employee benefit costs, is a risk.
• The company's ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures is a risk.
• The company's ability to replace the revenue from the terminated UnitedHealth Group contract is a risk.
• The company's financial performance is sensitive to changes in key assumptions, such as future reimbursement rates, interest rates, and labor costs.

Future Outlook

The company is focused on shifting business to Medicare Advantage contracts with improved rates and is working to replace revenue from the terminated UnitedHealth Group contract. The company is also evaluating the impact of the 2025 Home Health Final Rule on its operations.

Management Comments

• Management believes Adjusted EBITDA assists investors in comparing our operating performance across operating periods on a consistent basis by excluding items we do not believe are indicative of our operating performance.
• Management believes the 2025 Hospice Final Rule will result in a net increase to our Medicare payment rates of approximately 4% effective for services provided beginning October 1, 2024.

Industry Context

The healthcare industry is highly regulated, and providers are routinely subject to litigation. Changes in reimbursement rates and regulatory developments can significantly impact the company's financial performance. The company is also facing challenges related to staffing and cost control.

Comparison to Industry Standards

• Enhabit is the fourth-largest provider of home health services and a leading provider of hospice services nationally, measured by 2022 Medicare revenues.
• The company's performance is impacted by changes in Medicare and Medicare Advantage reimbursement rates, which are common factors affecting all companies in the home health and hospice industry.
• The company's focus on shifting business to Medicare Advantage contracts is a common strategy among healthcare providers to improve revenue.
• The company's cost control initiatives are also a common practice in the industry to improve profitability.
• The goodwill impairment charge is a significant event that is specific to Enhabit and its valuation of its assets.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal actions, proceedings, and claims, as well as regulatory and other governmental audits and investigations.
• The company is a plaintiff in a lawsuit styled Enhabit, Inc. et al. v. Nautic Partners IX, L.P., et al., asserting claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity.

Related Party Transactions

• The company has entered into several agreements with Encompass that govern the relationship of the parties following the Distribution, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement, and an Employee Matters Agreement.
• The company incurred costs of approximately $1.2 million and $3.6 million, respectively, in connection with the usage of Medalogix's analytics platforms during the three and nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and goodwill impairment.
• Employees may be affected by cost control initiatives and potential restructuring activities.
• Customers (patients) may experience changes in service delivery due to the termination of the UnitedHealth Group contract.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to negotiate a new agreement with UnitedHealth Group.
• The company will work to replace the revenue from the terminated UnitedHealth Group contract with other payors.
• The company will continue to evaluate the impact of the 2025 Home Health Final Rule on its operations.
• The company will continue to focus on cost control initiatives.

Key Dates

Keywords

home health, hospice, goodwill impairment, net service revenue, adjusted EBITDA, Medicare, reimbursement rates, contract termination, financial results, healthcare services